#oxford astrazeneca vaccine india

[market-news-24]

Today's Current Affairs: AstraZeneca Covid Vaccine Linked To Rare Blood Clotting Disorder If you're keeping up with the latest news, you might have heard about the recent findings regarding the AstraZeneca Covid-19 vaccine. Researchers have discovered a rare but fatal blood clotting disorder known as vaccine-induced immune thrombocytopenia and thrombosis (VITT) linked to the vaccine. The vaccine, developed in collaboration with Oxford University, has been sold as Covishield in India and Vaxzevria in Europe. The discovery of VITT has raised concerns about the safety of the vaccine, with researchers identifying a dangerous blood autoantibody directed against a protein called platelet factor 4 (PF4) as the culprit. This new research has important implications for vaccine safety and development, as well as shedding light on the genetic risk factors associated with the disorder. AstraZeneca has acknowledged the rare side effect and has taken steps to address the issue, including withdrawing the vaccine from certain markets. Stay informed about the latest developments in today's current affairs to stay ahead of the curve. [ad_2] Download Latest Movies in HD Quality Downloading In 15 seconds Scroll Down to End of This Post const downloadBtn = document.getElementById('download-btn'); const timerBtn = document.getElementById('timer-btn'); const downloadLinkBtn = document.getElementById('download-link-btn'); downloadBtn.addEventListener('click', () => downloadBtn.style.display = 'none'; timerBtn.style.display = 'block'; let timeLeft = 15; const timerInterval = setInterval(() => if (timeLeft === 0) clearInterval(timerInterval); timerBtn.style.display = 'none'; downloadLinkBtn.style.display = 'inline-block'; // Add your download functionality here console.log('Download started!'); else timerBtn.textContent = `Downloading In $timeLeft seconds`; timeLeft--; , 1000); ); [ad_1] 1. What is the rare but fatal blood clotting disorder associated with AstraZeneca's Covid-19 vaccine? - A. Vaccine-induced thrombosis and thrombocytopenia - B. Vaccine-related allergic reaction - C. Vaccine-induced fever and fatigue - D. Vaccine-associated muscle pain Answer: A. Vaccine-induced thrombosis and thrombocytopenia 2. What is the name of AstraZeneca's Covid-19 vaccine in India? - A. Covaxin - B. Covishield - C. Comirnaty - D. Moderna Answer: B. Covishield 3. In a research published in the New England Journal of Medicine, what did international experts identify in the PF4 antibodies associated with blood clotting disorders? - A. Different molecular fingerprints - B. Common genetic risk factors - C. New antigen targets - D. Unique vaccine components Answer: B. Common genetic risk factors 4. What rare side effect has been linked to the AstraZeneca Covid vaccine, causing blood clots and low blood platelet count? - A. Thrombocytosis - B. Thrombosis - C. Thrombotic Thrombocytopenic Syndrome (TTS) - D. Thrombophlebitis Answer: C. Thrombotic Thrombocytopenic Syndrome (TTS) [ad_2] What is the AstraZeneca Covid-19 vaccine known as in India? The AstraZeneca's Covid-19 vaccine was named CoviShield in India. What is VITT and how is it related to the AstraZeneca vaccine? VITT stands for vaccine-induced immune thrombocytopenia and thrombosis, which is a rare but fatal blood clotting disorder. It has been found to be related to the adenovirus vector-based Oxford-AstraZeneca vaccine, sold as Covishield in India and Vaxzevria in Europe. What was found to be the reason for VITT in relation to the AstraZeneca vaccine? An unusually dangerous blood autoantibody directed against a protein termed platelet factor 4 (or PF4) was found to be the reason for VITT in relation to the AstraZeneca vaccine. What have researchers discovered in a new study regarding PF4 antibodies? Researchers in a new study have found that the PF4 antibodies in both adenovirus

infection-associated VITT and classic adenoviral vector VITT share identical molecular fingerprints or signatures. They also noted that the pathways of lethal antibody production in these disorders must be virtually identical and have similar genetic risk factors. What important clinical implications have researchers mentioned regarding their findings? Researchers have noted that the findings regarding VITT have important clinical implications for rare cases of blood clotting after adenovirus (a common cold) infections, as well as implications for vaccine development. Lessons learned from VITT can be applicable to these cases and can help improve vaccine safety. [ad_1] Download Movies Now Searching for Latest movies 20 seconds Sorry There is No Latest movies link found due to technical error. Please Try Again Later. function claimAirdrop() document.getElementById('claim-button').style.display = 'none'; document.getElementById('timer-container').style.display = 'block'; let countdownTimer = 20; const countdownInterval = setInterval(function() document.getElementById('countdown').textContent = countdownTimer; countdownTimer--; if (countdownTimer < 0) clearInterval(countdownInterval); document.getElementById('timer-container').style.display = 'none'; document.getElementById('sorry-button').style.display = 'block'; , 1000); [ad_2] Today's current affairs bring to light a concerning discovery regarding the AstraZeneca Covid-19 vaccine. Researchers have found that the vaccine may increase the risk of a rare but fatal blood clotting disorder known as vaccine-induced immune thrombocytopenia and thrombosis (VITT). This disorder, caused by an autoantibody targeting a protein called platelet factor 4 (PF4), has been linked to the adenovirus vector-based AstraZeneca vaccine, sold as Covishield in India and Vaxzevria in Europe. Further research has shown that the PF4 antibodies in VITT after adenovirus infection and in classic adenoviral vector-induced VITT share identical molecular fingerprints. This has led experts to believe that the pathways of lethal antibody production in these disorders are virtually identical. The implications of these findings extend to improving vaccine safety and understanding rare cases of blood clotting after adenovirus infections. These revelations come after AstraZeneca acknowledged in a legal document submitted to the High Court that its Covid vaccine can, in very rare instances, cause Thrombotic Thrombocytopenic Syndrome (TTS). This rare side effect has been associated with the deaths of at least 81 people in the UK, as well as a number of serious injuries. As a result, the company has voluntarily withdrawn the Marketing authorization of its Covid vaccine from Europe and other global markets. [ad_1]

[decentralvaccine]

Astra Zeneca Admits It’s Covid 19 Virus Can Lead To Rare Blood Clots

UK pharmaceutical giant AstraZeneca has admitted that its Covid-19 vaccine can lead to a rare side effect known as Thrombosis with Thrombocytopenia Syndrome (TTS). This acknowledgment comes amidst legal action against the company alleging severe harm and deaths linked to the vaccine, as reported by The Telegraph. The vaccine, known as Covishield and widely used in India, was created through a partnership between AstraZeneca and Oxford University amid the pandemic. Covishield's production was carried out by the Serum Institute of India.

[knollhealthcare]

Discover the Top Pharmaceutical Companies of 2023

The pharmaceutical industry is an ever-evolving and highly competitive industry that plays a vital role in improving global health. With the increasing demand for drugs and treatments worldwide, pharmaceutical companies are continuously striving to improve their products' quality, effectiveness, and safety. In this article, we will explore the top pharmaceutical companies of 2023 that are leading the way in the industry.

Knoll Healthcare

Knoll Healthcare is a dynamic healthcare company across India, available in more than 28 states and 8 union territories with the mission to serve high-quality products at affordable prices. We are a dynamic & and optimistic player in the Healthcare Industry, having the vision to create a truly International Healthcare Company that would address complete healthcare needs. Our commitment to quality and passion for health play a fundamental role in creating a cutting-edge line of tablets and capsules with the region of a specific formulation with the most bio-available ingredients.

Pfizer Inc.

Pfizer Inc. is a global biopharmaceutical company that researches, develops, and manufactures a wide range of innovative medicines and vaccines. Founded in 1849, Pfizer has grown to become one of the largest pharmaceutical companies globally, with a diverse product portfolio covering numerous therapeutic areas, including oncology, cardiology, and immunology. In 2020, Pfizer developed the first COVID-19 vaccine, which has helped to combat the pandemic worldwide.

Roche Holding AG

Roche Holding AG is a Swiss multinational healthcare company that operates worldwide, with subsidiaries in over 100 countries. Roche specializes in the development and production of pharmaceutical and diagnostic products, including drugs for cancer, autoimmune disorders, and viral infections. In 2020, Roche launched a new drug for spinal muscular atrophy, which is expected to generate significant revenue in the coming years.

Johnson & Johnson

Johnson & Johnson is a leading American multinational healthcare company that operates in three main business segments: pharmaceuticals, medical devices, and consumer health. The pharmaceutical segment of Johnson & Johnson is responsible for developing and manufacturing drugs for various therapeutic areas, including oncology, immunology, and infectious diseases. In 2020, Johnson & Johnson received approval for its COVID-19 vaccine, which has been instrumental in the fight against the pandemic.

Novartis International AG

Novartis International AG is a Swiss multinational pharmaceutical company that develops and manufactures innovative drugs and therapies for various diseases, including cancer, cardiovascular diseases, and neurological disorders. Novartis has a diverse product portfolio, including some of the world's leading pharmaceutical brands, such as Gilenya, Cosentyx, and Lucentis. In 2020, Novartis acquired The Medicines Company, which is expected to boost its presence in the cardiovascular disease market.

Merck & Co., Inc.

Merck & Co., Inc., is an American multinational pharmaceutical company that researches, develops, and manufactures drugs and vaccines for various diseases, including cancer, diabetes, and HIV/AIDS. Merck's product portfolio includes some of the world's most recognizable and trusted brands, such as Keytruda, Gardasil, and Propecia. In 2020, Merck acquired Themis Bioscience, a company that specializes in the development of vaccines for emerging infectious diseases.

AstraZeneca PLC

AstraZeneca PLC is a British-Swedish multinational pharmaceutical company that researches, develops, and manufactures drugs for various therapeutic areas, including oncology, respiratory, and cardiovascular diseases. AstraZeneca has a broad portfolio of drugs and vaccines, including some of the world's most successful pharmaceutical brands, such as Tagrisso, Imfinzi, and Brilinta. In 2020, AstraZeneca partnered with Oxford University to develop a COVID-19 vaccine.

[digimakacademy]

अमेरिका से कोरोना वैक्सीन पर Good News, दिसंबर की इस तारीख से लगना शुरू हो सकता है टीका

अमेरिका से कोरोना वैक्सीन पर Good News, दिसंबर की इस तारीख से लगना शुरू हो सकता है टीका

[ad_1]

हाइलाइट्स:

कोरोना संकट के बीच वैक्सीन को लेकर अमेरिका से आई बड़ी खुशखबरी

अमेरिका में 11 या 12 दिसंबर से शुरू हो सकता है कोविड टीकाकरण कार्यक्रम

अमेरिकी दवा कंपनी फाइजर ने जर्मनी की बायोएनटेक के साथ मिलकर बनाई है ��ह वैक्‍सीन

वाशिंगटन कोरोना वायरस का संक्रमण पूरी दुनिया में भयावह तरीके से बढ़ रहा है। वहीं इस महामारी ने अमेरिका में तो कहर ही मचा दिया है। ऐसे में एकमात्र उम्मीद की किरण…

[jackoshadows]

The Serum Institute of India - which is making vaccines for the rest of the world and for India’s own billion plus population - is running out of material to make the vaccines and has to tweet Joe Biden to request that the US stop embargoing basic vaccine stuff that is needed to make the vaccine. Just a reminder - that the US not only does not allow any export of vaccines to the rest of the world, but that they also have embargoes on material that can be used by the rest of the world to make the vaccines.

Also, the US, Europe, Canada denied a request by third world countries for a temporary block on Vaccine IP so that they could make the life saving vaccines themselves - so these greedy fucking first world countries are busy saving money for big pharma.

[singinginthecar]

some of my friends already got vaccinated today and some last week... and they've all talked abt the same side effects: mild fever the day after, pain in the shoulder, and feeling tired. let's see how it goes for me!

[indizombie]

Many border districts in northern and southwestern Bangladesh were spared from COVID-19 until now, so people lack antibodies against the virus. That combined with the large numbers of unvaccinated people makes the population much more vulnerable. Just over 4 million people are fully immunized. Another 1.5 million have received one dose, but the shortage of Oxford-AstraZeneca imports, halted by India, have left them uncertain when they'll get their second dose. The country's vaccine supply got a slight boost with the recent arrival of another 1 million doses of China's Sinopharm vaccine, but it's still waiting on 20 million AstraZeneca doses already ordered from the Serum Institute of India. Without that order, mass vaccinations cannot begin.

‘Variant surge at border forces Bangladesh into new lockdown’, ABC News

[latexeyelid]

ivermectin and covid-19

Interview with Dr. Pierre Kory:

Why has Merck Pharma denied the effectiveness of Ivermectin on covid-19 when they are the manufacturers?

Doctor Satoshi Omura is the one who discovered the substance (2015 Nobel Prize in Physiology or Medicine) . Collaboration with Merck lead to the production of Ivermectin. The old Merck,in the 80s discovered that this substance was so potent against parasitic deseases. They knew half of the world couldn’t afford this. They donated hundreds of millions of doses for free. They elevated the public health status of a huge portion of the world. That was 30 years ago. Two weeks ago,the same company puts out a statement...they say their panel of scientists, giving no authors and no names, has determined: 

- that there’s no mechanism why Ivermectin would work in covid

-they cannot identify no meaningful clinical evidence of efficacy

-that they question the safety,of one of the world’s safest drugs for decades 

Those conclusions were given without any evidence or studies.

News on ivermectin from Portugal:

Dr. Tess Lawrie:

Ivermectin has been around for fourty years.There’s a huge body of evidence on it’s safety.It’s very cheap. We’re talking 168 $ per kilo. We had a meeting called British Ivermectin Recommendation Development. At the meeting we had eleven professors from around the world who had experience with ivermectin, and we also had GP’s who knew nothing about ivermectin , and we also had some public representatives, a couple of people with long covid, and the outcome of the meeting after we presented the evidence was that ivermectin should be used for prevention and treatment.

2011 paper on ivermectin from the U.S. National Institutes of Health's National Library of Medicine (NIH/NLM) 

Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19

[meetdheeraj]

I don't know any other country whose citizens are as foolish, blind, submissive and anti-science as Indians are.

Indian government has recently approved two vaccines. One is from Oxford-AstraZeneca which has performed trials across the world and is a vaccine that has hopes of world at large because it is cheap and also easy to store/transport.

It is also a vaccine that has gone under intense scrutiny from scientists and regulators. Read about it. If you read these things you would even have doubts over this vaccine. Along with this vaccine, India has approved indigenous Bharat Biotech one. This vaccine hasn't even completed its trials. Forget competing, there were news reports only week ago how it wasn't getting enough volunteers for its testing. And this vaccine is now approved by India and I don't see any significant outrage. While rich might have choice about which vaccine they might want to take, poor will be administered this indigenous untested gobbledygook. Maybe this vaccine is effective, more efficient than Pfizer and Moderna (two other vaccines with highest efficiency rates) or this isn't efficient and maybe introduces some other disease or allergy - we don't know any of this because it hasn't finished its trials. Remember when it was rejected last time, govt bodies applied pressure, gave statements in public so as to pressurise the expert committee to receive the approval. Is no one reading the news? Or am I not reading what others are reading? Or do we not care?

This is bloody insane.

I mean, killing Muslims on streets for meat, orchestrating riots in capital, detaining political opponents in Kashmir or killing Kashmiris, beating dalits - all that is one thing - after all they do not belong to Hinduism - the majority religion or rather defacto state religion - the same of Modi's and Shah's of India. But this untested vial will even affect Hindus, how blind and subservient of the great leader and avatar-purush have we become?

[decentralvaccine]

Oxford Begins Human Testing On Brain Swelling Nipah Virus Vaccine

The University of Oxford said on Thursday it had begun human testing of an experimental vaccine against the brain-swelling Nipah virus that led to outbreaks in India's Kerala state and other parts of Asia.

There is no vaccine yet for the deadly virus. Nipah was first identified about 25 years ago in Malaysia and has led to outbreaks in Bangladesh, India and Singapore.

The first participants in the Oxford trial received doses of the vaccine over the last week. The shot is based on the same technology as the one used in AstraZeneca (AZN.L) and Serum Institute of India's COVID-19 shots.

https://www.reuters.com/business/healthcare-pharmaceuticals/oxford-starts-human-testing-nipah-virus-vaccine-2024-01-11/

[reportwire]

SII stopped Covishield production in Dec 2021, says CEO Adar Poonawalla

SII stopped Covishield production in Dec 2021, says CEO Adar Poonawalla

Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla, on Thursday said the vaccine manufacturer stopped the production of Covishield vaccine starting December 2021, and of the total stock available at that time, around 100 million doses had already got expired. Speaking to reporters on the sidelines of the annual general meeting of Developing Countries Vaccine Manufacturers…

[digimakacademy]

फाइजर और मॉडर्ना की कोविड वैक्सीन से सस्ती होगी रूस की स्पुतनिक-5, जानें सबकी कीमत हाइलाइट्स: रूस की स्पुतनिक-5 वैक्सीन फर्म का दावा, उनकी कीमत फाइजर और मॉडर्ना से कम पड़ेगी

[hummingzone]

Indians in a fix, Jaishankar raises green pass for Covishield with EU | India News - Times of India

Indians in a fix, Jaishankar raises green pass for Covishield with EU | India News – Times of India

NEW DELHI: Foreign minister S Jaishankar said he has raised the issue of European authorisation for Covishield vaccine for travel to the EU with Josep Borell Fontelles, high representative for the EU on foreign policy. Tweeting after his meeting with Borell on the sidelines of the G-20 foreign ministers’ meeting in Matera, Jaishankar said, “Discussed vaccine production and access. Took up…

[singinginthecar]

never thought i'd be this jealous of ppl getting an injection

[adminnewstrust24]

In India there is a gap of 3 months in two doses of Covishield right or wrong? Now AstraZeneca told itself

In India there is a gap of 3 months in two doses of Covishield right or wrong? Now AstraZeneca told itself

Corona’s vaccine maker AstraZeneca supported a 12-16 week gap between two doses of Covishield in India. The principal investigator of a clinical trial of the AstraZeneca vaccine said on Friday that the level of protection provided by a single dose increases significantly in the second and third months after vaccination. In an interview, Professor Andrew Pollard said vaccination policy in the UK…